Chantal Mathieu is Professor of Internal Medicine and Chair of Endocrinology at the University Hospital Gasthuisberg, Catholic University of Leuven (KULeuven), Belgium. Professor Mathieu received her medical degree and PhD from KULeuven, where she subsequently completed training in internal medicine and endocrinology.
Her clinical areas of interest include endocrinology, diabetes and the organisation of diabetes care. Her research activity is focused on the prevention of type 1 diabetes, effects of vitamin D on the immune system and diabetes, functioning of the insulin-producing beta cell, adjunct therapies in type 1 diabetes and novel glucose-lowering agents in type 1 and type 2 diabetes.
Professor Mathieu has authored and co-authored more than 400 peer-reviewed publications in international journals. She has served on the editorial boards of the Journal of Diabetes and its Complications (2012-14), Endocrinology (2013-19) and JSMBM (2013-), on the advisory boards of Diabetologia (2007-11), Lancet Diabetes Endocrinology (2019-) and was Associate Editor of Diabetologia from 2003-06. In 2013, she received the prestigious InBev-Baillet Latour Prize for Clinical Research for her pioneering research on the pathogenesis of type 1 diabetes. She presently co-ordinates the INNODIA project on prevention and intervention in type 1 diabetes in Europe.
Professor Mathieu was appointed Teacher of Trainees in Endocrinology in 1998 and has been a full professor at KULeuven since 2002. In that time she has been programme director of Leuven’s Biomedical Sciences (2006-16), received the Best Teacher award every year between 2015 and 2018, and has supervised 18 PhD theses and over 10 master theses. She has been Senior Vice-President of the EASD since 2019 and currently serves as its Chair of Postgraduate Education. In 2019 she became Chair of the EUDF.
Duality of Interest: Professor Mathieu has received research support/grants from ActoBio Therapeutics, Medtronic, Novartis, Novo Nordisk and Sanofi and speaker’s fees/honoraria from AstraZeneca, Boehringer Ingelheim, Eli Lilly & Company, Novartis, Novo Nordisk and Sanofi. She has also received payments for membership of boards/advisory panels from ActoBio Therapeutics, AstraZeneca, Boehringer Ingelheim, Eli Lilly & Company, Insulet, Medtronic, Merck Sharpe and Dohme Ltd, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, Zealand Pharma, Imcyse, Avotres, Vertex and Provention Bio.
Date: Autumn 2022